EAN Communications Committee member Agne Straukiene talks to Prof. Riccardo Soffietti, who delivered the Camillo Golgi Lecture at the 12th Congress of the European Academy of Neurology

Dementia imposes huge cost across 30 high-income European countries, with families and unpaid informal carers carrying much of the burden, according to the COIN-Eu study published in the Journal of Alzheimer’s Disease.

EAN Mentorship Programme participants convened for a special Career Development Session workshop at the annual EAN Congress 2026 in Geneva

The 20 participants of the second cohort of the EAN Leadership Programme (2025-2027) met in person for their second workshop at the EAN Congress 2026 in Geneva

Project Coordinator of the Greek Brain Health School Challenge looks back on a powerful example of young people engaging with complex health topics

eanNews Editor Benedetta Bodini talks to Prof. Daniela Berg, who delivered the Moritz Romberg Lecture at the EAN Congress 2026

A new collection of Interactive Cases, Webinar Recordings, and Interactive Modules is ready for you to explore at your own pace.

Thanks to this year's group of authors who gave their time, attention, and expertise to report on some of the most relevant sessions of this year’s congress.

This EAN TV Session, organised by the Resident & Research Fellow Section, explored how AI is transforming neurology

On 5 June 2026, the Kosovo Society of Neurology and the EAN held a successful EAN Regional Teaching Day in Prishtina, Kosovo, as part of the Society’s annual Spring Conference

Our summary of neurological news items the European Medicines Agency (EMA) monthly Human Medicines Newsletter.

Explore eight new eanCampus Spotlight Modules this summer, featuring expert-curated neurology content and a chance to win an EAN Congress 2027 registration.

This thought-provoking EAN TV session brought together leading African neurology experts, exploring the continent’s evolving neurological health challenges.

A full audience for this session reflected the growing interest in CIDP, autoimmune nodopathies and complement-targeted therapies.

Can someone have Alzheimer's disease before they develop symptoms? This fascinating workshop explored why the answer depends on how we define the disease—and why that debate matters more than ever in the era of disease-modifying therapies.